2006 Innovation Operations Pharmaceuticals 
Harvard Business Review
SEPTEMBER 20, 2011
A vast ideological gap on macro-economic policy divides Washington and much of the nation, but there is almost universal agreement on one solution: innovation. Innovation is now perceived as a panacea for job creation, income generation, economic growth, dollar strength, and the revival of the U.S. as global hegemon.
Harvard Business Review
FEBRUARY 10, 2014
Back in 2006, my colleague Huggy Rao and I launched an executive education program at Stanford called “Customer-focused Innovation.” Mornings consisted of lectures and case studies in a traditional classroom in the Stanford Business School; this was the “clean models” part of the program.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Strategy Driven
MARCH 18, 2011
To demonstrate it, we’ve examined a number of industries and mapped the level of capabilities coherence in the portfolio of each of the major players against their operating margins over the past five years. Companies today operate in a business environment that encourages incoherence. We call this measure the ‘coherence premium.’
Harvard Business Review
OCTOBER 26, 2011
Between 2006 and 2008, more than $1 billion venture-capital dollars were channeled into startups focused on solar, wind and biofuel technologies. When biotechnology startups like Genentech began to acquire other startups to retain their edge, pharmaceutical incumbents were forced to enter the acquisition melee to remain competitive.
Harvard Business Review
JUNE 20, 2017
Multinational companies operating in Mexico are facing a great deal of uncertainty. Firms in innovation-driven industries, such as pharmaceuticals and medical devices, have long supported greater standardization across borders, with stronger intellectual property protections and enforcement of regulatory standards.
Expert insights. Personalized for you.
12 
Let's personalize your content